DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price Up 13.3% Following Analyst Upgrade

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) rose 13.3% on Friday after Wells Fargo & Company raised their price target on the stock from $12.00 to $13.00. Wells Fargo & Company currently has an equal weight rating on the stock. DENTSPLY SIRONA traded as high as $14.48 and last traded at $14.4060. Approximately 4,743,575 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 4,667,831 shares. The stock had previously closed at $12.71.

XRAY has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Mizuho raised their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Stifel Nicolaus set a $13.00 target price on DENTSPLY SIRONA in a research report on Thursday, November 6th. UBS Group decreased their price target on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Finally, Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $14.00.

Insiders Place Their Bets

In related news, Director Gregory T. Lucier sold 82,200 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $11.14, for a total value of $915,708.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XRAY. Daiwa Securities Group Inc. boosted its stake in shares of DENTSPLY SIRONA by 2.9% during the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after buying an additional 767 shares during the period. Arizona State Retirement System raised its holdings in shares of DENTSPLY SIRONA by 1.4% during the third quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock worth $748,000 after acquiring an additional 807 shares in the last quarter. True Wealth Design LLC raised its holdings in shares of DENTSPLY SIRONA by 49.7% during the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 1,181 shares in the last quarter. Sivia Capital Partners LLC boosted its position in DENTSPLY SIRONA by 5.3% during the third quarter. Sivia Capital Partners LLC now owns 25,774 shares of the medical instruments supplier’s stock valued at $327,000 after purchasing an additional 1,293 shares during the last quarter. Finally, Empowered Funds LLC grew its stake in DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Stock Performance

The firm has a 50-day simple moving average of $12.42 and a two-hundred day simple moving average of $12.48. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of -4.89, a price-to-earnings-growth ratio of 1.15 and a beta of 1.01. The company has a current ratio of 1.47, a quick ratio of 0.99 and a debt-to-equity ratio of 1.36.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). The firm had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 17.62%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -14.48%.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.